Navigation Links
Takeda San Francisco Enters Into A Sponsored Research Agreement With UCSF
Date:9/21/2009

SOUTH SAN FRANCISCO, Calif., Sept. 21 /PRNewswire/ -- Takeda San Francisco, Inc. (TSF), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, announced today that it has entered into a sponsored research collaboration with the University of California, San Francisco. The research program will focus on therapeutic antibody discovery and development to an undisclosed target. The agreement will solely support specific research conducted in the laboratory of Charles Craik, Ph.D., who will serve as the principal investigator for the project. This agreement enhances TSF's initiative to build a robust preclinical antibody therapeutics pipeline by leveraging the company's comprehensive and proprietary antibody technology platform and novel discovery, optimization and development technologies.

"This partnership is another example of UCSF's increasing commitment to using its world-class biomedical research programs to bring direct benefit to patients," said Dr. Regis Kelly, Executive Director of QB3, the California Institute for Quantitative Biosciences, one of four California Institutes for Science and Innovation.

"We're pleased to work with Dr. Craik, who is a leader in the field of proteases associated with disease pathogenesis," said Dr. Mary Haak-Frendscho, President and CSO of TSF. "We believe this research will help enable the discovery and development of a novel antibody product candidate to preclinical proof of concept. It furthermore demonstrates our commitment to working with academic experts concerning the development of novel biologic targets for the treatment of disease."

About Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antibody IND Engine for human antibody therapeutics for the treatment of cancer, inflammation and metabolic diseases. TSF supports Takeda's therapeutic antibody initiative in close collaboration with Takeda's other R&D organizations. Additional information about Takeda San Francisco is available at http://www.takedasf.com.

About Takeda Pharmaceutical Company, Limited.

Founded in 1781 and located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

About UCSF-Craik Laboratory

Dr. Charles Craik is a Professor of Pharmaceutical Chemistry at UCSF. His laboratory is focused on the role of protease structure and mechanisms of essential proteins associated with both normal and dysfunctional biological processes using novel genetic, biochemical and biophysical methods. Dr. Craik has pioneered new combinatorial technologies to probe protein-protein interaction interfaces and identify inhibitors in addition to developing an array of new expression methods to better address protein structure and function.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For further information, please visit www.ucsf.edu.

Disclaimer

The information stated above was prepared by Takeda San Francisco and reflects solely the opinion of the company. Nothing in this statement shall be construed to imply any support or endorsement of Takeda, or any of its products, by The Regents of the University of California, its officers, agents and employees.


'/>"/>
SOURCE Takeda San Francisco, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
2. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
3. Chemizon Announces Research Collaboration Expansion With Takeda
4. Takeda submits new drug application for alogliptin (syr-322) in the US
5. Takeda Announces New U.S. Leadership
6. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
7. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
8. Takeda Completes Acquisition of Millennium
9. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
10. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
11. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
Breaking Medicine Technology: